Business Wire

ADVA

15.12.2020 09:02:11 CET | Business Wire | Press release

Share
ADVA launches new generation of edge and access clocks for 5G network timing

ADVA (FSE: ADV) today launched a unique set of edge and access network synchronization devices with enhanced capabilities for next-generation applications such as 5G. The latest Oscilloquartz solutions address key challenges for a wide range of industries by bringing new levels of timing accuracy and resilience to edge networks. The OSA 5412 and 5422 offer precise phase, frequency and time-of-day synchronization and can be used for time-as-a-service applications. For the first time, communication service providers, enterprises, broadcast networks and power utilities can deploy synchronization technology at the edge that features multi-band GNSS receivers for nanosecond accuracy. The OSA 5412 and 5422 utilize in-service sync probing and assurance as well as innovative GNSS assurance capabilities. The products also provide support for eight field-upgradeable 10Gbit/s ports, ensuring the scale and efficiency needed for next-generation smart grids, industrial IoT applications and 5G connectivity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201215005081/en/

“Our latest solutions build on the great success we’ve had with our access synchronization product line. Now operators can harness the power of multi-band GNSS receivers to deliver highly accurate, UTC-traceable timing at the network edge. That enables the availability and precision that will be essential for tomorrow’s services,” said Nir Laufer, senior director, product line management, Oscilloquartz, ADVA. “By extending the feature set of our edge technology, we’re empowering CSPs to smoothly transition to the reliability and accuracy required for 5G and, at the same time, enabling our unique innovation to be used across a wide range of verticals. With support for 10Gbit/s and 1Gbit/s interfaces as well as hardware timestamping, our access timing products are the ultimate in future-proof, space-efficient synchronization.”

The OSA 5412 is a highly flexible access network synchronization solution that offers compact and cost-effective timing distribution and assurance. The OSA 5422 is engineered for the most extreme conditions. It meets stringent frequency and phase synchronization requirements, delivers the best holdover performance of any edge device on the market, and supports multiple legacy interfaces such BITS and IRIG. Both solutions address new ITU-T specifications, including for class A and B PRTCs, ePRTCs with strict holdover requirements, and the newly improved class C and D boundary clocks. They also feature onboard multi-band, multi-constellation GNSS receivers that overcome ionospheric delay variation far more cost-efficiently than rival solutions using high-end rubidium oscillators. The OSA 5412 and 5422 support multiple PTP profiles, NTP and SyncE with the highest number of 1/10GbE ports on the market. What’s more, both devices are engineered with optional OLED display and with hot-swappable modules and power supplies to be easily upgraded in the field.

“Access grandmaster clocks need to meet stricter demands for accuracy and reliability than ever before, and many industries have their own specific set of stringent timing requirements. That’s why we’ve evolved our portfolio of edge and access network synchronization solutions for the specific challenges of the 5G era,” commented Gil Biran, general manager, Oscilloquartz, ADVA. “Our OSA 5412 and 5422 answer the most urgent timing needs of mission-critical infrastructure in multiple verticals. They provide nanosecond precision, an abundance of fan-out interface options and operational simplicity thanks to the management and monitoring capabilities of our Ensemble Controller with Sync Director. Operators of broadcast, healthcare, financial networks and more now have a straightforward and affordable path from legacy to next-generation timing.”

Further information on the OSA 5412 and 5422 is available in these slides: https://adva.li/osa-5412-5422-slides .

About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About Oscilloquartz

Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at www.oscilloquartz.com .

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye